NCT06186869Recruiting
Effects of Two Different Exercise Programs and Diet in Obese Subjects With NAFLD
Effects of Two Different Exercise Programs Combined With the Mediterranean Diet on Inflammatory Status in Subjects With Obesity and NAFLD
Source: ClinicalTrials.gov · Last updated 27 Mar 2026
Brief summary (registry, in English)
The aim of the study is to estimate the effectiveness of two different exercise programs combined with the Mediterranean diet versus diet alone on inflammatory status in subjects aged 18-65 years with obesity (BMI\>30) and Non-Alcoholic Fatty Liver Disease (NAFLD) (CAP \>248 dB/m).
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 90 (estimated)
- First submitted
- 9 Nov 2023
- Start date
- 2 Oct 2023
- Primary completion date
- 15 Dec 2025
- Lead sponsor
- Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis
- Diseases
- Obesity, Fatty liver disease (MASLD/MASH)
- NCT number
- NCT06186869
What you commit to
- Study type: Interventional
- Planned participants: 90
- From 2 Oct 2023 to the primary completion date, 15 Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Presence of any pathology that may influence the presence of steatosis apart from pathologies that are inclusion criteria, neurological and psychiatric pathologies, gastrointestinal, oncological and cardiovascular diseases
Other
- Normal and underweight subjects
- Pregnancy or breastfeeding
- Subjects with osteoarticular pathologies that may prevent regular exercise
- Inability to quantify the degree of NAFLD by Fibroscan
- Person not in possession of a medical certificate of fitness for non-competitive physical activity.
Who the study is looking for
- BMI ≥ 30 kg/m2 or an abdominal circumference (waist) \> 94 cm in men and \> 80 cm in women (IDF criteria for the definition of abdominal obesity) with or without the characteristics that characterise metabolic syndrome
- Age range 18-65 years, both sexes
- Diagnosis of hepatic steatosis, formulated on the basis of recognised criteria (fibroscan (CAP (controlled attenuation parameter) \> 238 dB/m)).
Age in the registry: 18 years to 65 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| IRCCS De Bellis Coordinator of this site? Confirm its status | Castellana Grotte | Italy | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.